NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS [Yahoo! Finance]
NeuroSense Therapeutics Ltd. (NRSN)
Company Research
Source: Yahoo! Finance
progression was slowed by 33% (p=0.007), demonstrated in a 58% improvement in survival rates Consistent data across subgroups underscore the potential of PrimeC to redefine the standard of care in the treatment of ALS CAMBRIDGE, Mass. Dec. 4, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, is pleased to announce today statistically significant positive results from the 18-month data analysis of the PARADIGM study, evaluating the efficacy of PrimeC in the treatment of Amyotrophic Lateral Sclerosis (ALS). These results highlight a significant improvement in ALS Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for patients receiving PrimeC from the start compared to those who started on placebo. The study revealed a significant difference of nearly 8 points in ALSFRS-R between the group treated with PrimeC for 18 months
Show less
Read more
Impact Snapshot
Event Time:
NRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRSN alerts
High impacting NeuroSense Therapeutics Ltd. news events
Weekly update
A roundup of the hottest topics
NRSN
News
- NeuroSense Therapeutics files to sell 5.28M ordinary shares for holders [Seeking Alpha]Seeking Alpha
- NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS [Yahoo! Finance]Yahoo! Finance
- NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALSPR Newswire
- NeuroSense Provides Business Update and Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- NeuroSense Provides Business Update and Third Quarter 2024 Financial ResultsPR Newswire
NRSN
Sec Filings
- 12/26/24 - Form F-3
- 12/23/24 - Form 6-K
- 12/18/24 - Form 6-K
- NRSN's page on the SEC website